Top Page
Sino Biopharmaceutical
(OTC:1177)
Sino Biopharmaceutical (1177) vs. S&P 500 (SPY)
Sino Biopharmaceutical Business Overview & Revenue Model
Sino Biopharmaceutical Financial Statement Overview
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 26.20B | 28.78B | 26.86B | 23.65B | 24.23B | Gross Profit |
| 21.21B | 22.98B | 21.53B | 18.46B | 19.31B | EBIT |
| 5.79B | 6.69B | 18.86B | 4.89B | 5.81B | EBITDA |
| 6.98B | 6.69B | 19.87B | 6.54B | 7.37B | Net Income Common Stockholders |
| 2.33B | 5.00B | 14.61B | 4.34B | 4.69B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 14.12B | 16.92B | 15.79B | 16.43B | 19.11B | Total Assets |
| 63.60B | 64.06B | 60.54B | 47.21B | 58.30B | Total Debt |
| 12.58B | 13.98B | 12.12B | 14.21B | 8.62B | Net Debt |
| 3.13B | 5.33B | 2.52B | 3.59B | -2.02B | Total Liabilities |
| 25.43B | 26.12B | 22.81B | 24.79B | 18.01B | Stockholders Equity |
| 30.47B | 29.75B | 30.29B | 16.75B | 31.11B |
| Cash Flow | Free Cash Flow | |||
| 4.36B | 4.56B | 3.47B | 3.47B | 3.59B | Operating Cash Flow |
| 6.07B | 6.27B | 5.37B | 5.33B | 5.32B | Investing Cash Flow |
| -756.98M | -4.07B | -2.52B | -7.85B | -3.82B | Financing Cash Flow |
| -6.55B | -3.19B | -3.23B | 2.23B | 2.80B |
Sino Biopharmaceutical Technical Analysis
Sino Biopharmaceutical Peers Comparison
Sino Biopharmaceutical Corporate Events
Sino Biopharmaceutical Limited announced the details of its upcoming annual general meeting scheduled for June 10, 2025. Key agenda items include the adoption of financial statements for 2024, approval of a final dividend, re-election of several directors, and the re-appointment of Ernst & Young as auditors. The meeting will also consider resolutions to authorize the board to issue additional shares, potentially impacting the company’s capital structure and shareholder value.
Sino Biopharmaceutical Limited announced that its co-developed drug, penpulimab injection, has received approval from the US FDA for marketing. This approval marks a significant milestone as penpulimab is the only novel PD-1 monoclonal antibody with IgG1 subtype and Fc engineering, enhancing efficacy while minimizing adverse reactions. The drug is indicated for the treatment of recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) and has several approved indications in China. The company plans to further develop penpulimab’s indications and expand into international markets to address urgent clinical needs globally.
Sino Biopharmaceutical Limited announced that it will present 45 research results at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including 12 oral sessions and 4 Late-Breaking Abstracts. This participation highlights the company’s ongoing commitment to advancing cancer treatment, potentially enhancing its industry standing and offering significant insights for stakeholders involved in oncology research and development.
Sino Biopharmaceutical Limited’s board of directors has proposed the adoption of amended and restated articles of association to align with recent changes in the Hong Kong Stock Exchange’s Listing Rules, including the expansion of the paperless listing regime and the treasury shares regime. The proposed amendments aim to enhance clarity and make consequential changes, pending shareholder approval at the upcoming annual general meeting.
Sino Biopharmaceutical Limited announced that its self-developed drug, TQB3019 (BTK PROTAC), has been approved for clinical trials by China’s National Medical Products Administration. This drug targets hematologic tumors and represents a significant advancement in overcoming BTK inhibitor resistance, with promising preclinical results showing efficacy and safety. The company is also progressing with other related drug developments, aiming to address unmet clinical needs globally.
Sino Biopharmaceutical Limited announced that its application for a clinical trial of TQB6411, an EGFR/c-Met bispecific ADC, has been accepted by China’s Center for Drug Evaluation. TQB6411 is designed to target lung cancer driver genes, offering a potential treatment by blocking key signaling pathways and inducing cell death. The company has completed extensive pharmacological and safety verifications, showing promising results in vitro and in vivo. Alongside TQB6411, Sino Biopharmaceutical is also developing other drugs targeting EGFR and c-Met, highlighting its commitment to providing better treatment options for cancer patients worldwide.
Sino Biopharmaceutical Limited has received approval from the National Medical Products Administration of China to conduct a Phase I clinical trial for its self-developed drug TQB2101, intended for treating advanced malignant tumors. This approval marks a significant step in the company’s expansion of its ADC portfolio, which now includes four drugs in clinical stages. The trial will assess the safety and efficacy of TQB2101, which has shown promising preclinical results in targeting ROR1-positive tumors. This development is part of the company’s broader strategy to leverage its ADC technology platform to innovate and contribute to global health.
Sino Biopharmaceutical Limited announced positive results from a phase III clinical study of Culmerciclib in combination with Fulvestrant for first-line treatment of HR-positive and HER2-negative advanced breast cancer. The study showed that the combination therapy significantly reduced the risk of disease progression or death, achieving statistical significance and clinical relevance. This development positions the company to address the significant unmet clinical needs in breast cancer treatment, particularly for the most common subtypes, and strengthens its market presence in the oncology field.
Sino Biopharmaceutical Limited has announced a final ordinary cash dividend of HKD 0.04 per share for the financial year ending December 31, 2024. The dividend, subject to shareholder approval on June 10, 2025, will be paid on July 10, 2025, with the ex-dividend date set for June 16, 2025. This announcement reflects the company’s financial performance and commitment to delivering shareholder value, potentially impacting investor sentiment and market positioning.
Sino Biopharmaceutical Limited reported a significant financial performance for the year ending December 31, 2024, with a 10.2% increase in revenue to RMB 28.87 billion and a 24.9% rise in profit to RMB 6.36 billion. The company attributed its growth to increased sales of innovative and new products, which accounted for a larger share of revenue compared to the previous year. The Board recommended a final dividend of HK4 cents per share, reflecting the company’s strong financial health and commitment to shareholder returns.
Sino Biopharmaceutical Limited announced the publication of the results from a Phase Ib/IIa clinical study of their innovative drug, Rovadicitinib, in the journal Blood. Rovadicitinib, a first-in-class JAK/ROCK inhibitor, showed promising results in treating chronic graft-versus-host disease (cGVHD) with high response rates and favorable tolerability. The study’s publication highlights the drug’s potential as a new treatment option for cGVHD patients, and the company is advancing its clinical development globally, including applications and trials in China and the United States.
Sino Biopharmaceutical Limited has announced a board meeting scheduled for March 20, 2025, to approve the annual results for the year ending December 31, 2024, and to consider recommending a final dividend. This meeting is significant as it will provide insights into the company’s financial health and potential shareholder returns, impacting its market positioning and stakeholder interests.
Sino Biopharmaceutical Limited has announced a change in its Hong Kong branch share registrar and transfer office, effective from March 31, 2025. This change to Tricor Investor Services Limited is expected to streamline the process of share transfer registrations and collection of share certificates, potentially impacting stakeholders by enhancing operational efficiency.
Sino Biopharmaceutical Limited has signed an exclusive strategic cooperation agreement with Sciwind Biosciences for the development and licensing of the IL-29 project, known as CPX102, in 19 countries. CPX102 is a nebulized inhalation solution targeting respiratory syncytial virus (RSV) infections in children and is currently in Phase IIb clinical trials in China. This innovative treatment offers a broad-spectrum antiviral approach with potential applications for other respiratory viruses like SARS-CoV-2 and influenza. The agreement positions Sino Biopharmaceutical to potentially capture a significant market share in the respiratory/anti-infection field, addressing a large unmet clinical demand for effective RSV treatments.
Sino Biopharmaceutical has announced the approval for marketing of its new product, Loxoprofen Sodium Cataplasms, by the National Medical Products Administration of China. This product is notable for being the only loxoprofen sodium cataplasm in China to have passed the Consistency Evaluation and been validated through clinical trials. It offers increased efficacy and safety compared to oral preparations, enhancing patient compliance with its once-daily dosage. The approval strengthens Sino Biopharmaceutical’s product pipeline in surgery and analgesia, providing more treatment options for patients.
Sino Biopharmaceutical Limited has received approval from the National Medical Products Administration of China to market the first domestically produced tulobuterol patch for obstructive airway diseases. This innovative transdermal patch offers a more effective and convenient solution for asthma and other related conditions, particularly benefiting children due to its easy administration. The introduction of this patch not only breaks the monopoly of imported drugs but also addresses the supply challenges of asthma medication for children in China. This approval strengthens Sino Biopharmaceutical’s position in the market and supports its strategy to expand and enrich its product pipeline.